TrialThoracic cancer2020

Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.

Miso Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.